Originator Company: Human Genome Sciences Inc Active Companies:
As no development has been reported for some time, this program is assumed to be discontinued. Human Genome Sciences was investigating HG-1063, a program targeting human stem cell antigen-2 (lymphocyte antigen 6 complex, locus E; LY6E; RIG-E; SCA-2; TSA-1; retinoic acid induced gene E; thymic shared antigen 1), for the potential treatment of cancer and immune diseases. In August 2010, the company was seeking to outlicense rights to the technology [ 1122590 ].
No Development Reported
Lymphocyte antigen modulator